logo
logo
Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc.

NASDAQ•AVIR
CEO: Dr. Jean-Pierre Sommadossi Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-10-30
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
連絡先情報
225 Franklin Street, Suite 2100, Boston, MA, 02110, United States
857-284-8891
ateapharma.com
時価総額
$338.29M
PER (TTM)
-2.3
33.3
配当利回り
--
52週高値
$4.50
52週安値
$2.46
52週レンジ
92%
順位45Top 56.8%
3.6
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 3.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.53+43.24%
直近4四半期の推移

フリーCF

-$40.38M+75.28%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Loss Narrows Significantly Nine-month net loss narrowed $21.4M to $(113.5M); loss per share improved from $(1.60) to $(1.37).
R&D Spend Decreases Nine-month R&D expenses fell $18.2M to $100.2M, primarily due to completion of COVID-19 Phase 3 trial.
Cash Position Strengthened Net cash increased $12.6M for nine months, driven by $142.2M provided by investing activities from securities sales.
HCV Phase 3 Enrollment Ongoing Enrollment for HCV Phase 3 trials, C-Beyond and C-Forward, commenced in April and June 2025, respectively.

リスク要因

Substantial Future Funding Required Expect to incur substantial operating expenses and losses for the foreseeable future; profitability remains uncertain.
Dependence on HCV Candidate Success Business highly dependent on successful development and regulatory approval of the bemnifosbuvir/ruzasvir HCV regimen.
Intellectual Property Litigation Risk Gilead patents covering bemnifosbuvir may require licensing or result in costly infringement litigation if upheld.
Regulatory Approval Unpredictable Regulatory approval processes are lengthy, expensive, and inherently unpredictable, potentially delaying commercialization timelines.

見通し

Focus on HCV Phase 3 Completion Anticipate existing resources funding planned operations through 2027, focusing on completing HCV Phase 3 clinical development.
Workforce Reduction Yields Savings Workforce reduced 25% in Q1 2025, expected to result in aggregate cost savings of approximately $15.0M through 2027.
Share Repurchase Program Completed Completed $25.0M Share Repurchase Program, acquiring 3.1M shares in the quarter ended September 30, 2025.
Strategic Alternatives Review Open Concluded formal engagement with investment bank; remains open to strategic transactions post-HCV Phase 3 results.

同業比較

売上高 (TTM)

Vanda Pharmaceuticals Inc.VNDA
$216.11M
+8.7%
Arcturus Therapeutics Holdings Inc.ARCT
$92.04M
-35.4%
Enanta Pharmaceuticals, Inc.ENTA
$66.98M
+0.6%

粗利益率 (最新四半期)

ProQR Therapeutics N.V.PRQR
100.0%
+0.0pp
Voyager Therapeutics, Inc.VYGR
100.0%
+0.0pp
Arcturus Therapeutics Holdings Inc.ARCT
80.5%
-19.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
VTYX$999.48M-9.3-48.1%4.7%
OMER$811.10M-6.357.3%103.2%
TRDA$412.77M-4.3-26.4%12.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.49
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.53+43.2%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.44-8.3%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.40-46.7%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-2.00-22.7%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.37-7.5%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.48+41.2%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.75+74.4%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.63-17.3%
    不明